statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for RARE
 DateFirmActionFromTo Feb 2022Morgan StanleyMaintainsOverweight Feb 2022JP MorganUpgradesNeutralOverweight Feb 2022Morgan StanleyMaintainsOverweight
 View More Analyst...

Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange...

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Assenagon Asset Management S.A. lowered its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 32.4% in the fourth quarter, according to its most recent 13F filing...

Assenagon Asset Management S.A. Decreases Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

NOVATO, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ...

Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE)

This is a Bearish indicator signaling RARE's price could decline from here. Traders may explore shorting the stock or put options...

Ultragenyx Pharmaceutical (RARE, $50.58) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 8, 2024

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet...

Ultragenyx Pharmaceutical Earnings: No Visible Path To Financial Success Yet

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE  Get Free Report) insider John Richard Pinion sold 4,173 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an...

Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Insider Sells $224,340.48 in Stock

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Volume	625,791.00
52-Wk High	$54.98
52-Wk Low	$31.52

RARE Ultragenyx Pharmaceutical Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals